-
Why metal prices are soaring to record highs
-
Stocks tepid in thin pre-Christmas trade
-
UN experts slam US blockade on Venezuela
-
Bethlehem celebrates first festive Christmas since Gaza war
-
Set-piece weakness costing Liverpool dear, says Slot
-
Two police killed in explosion in Moscow
-
EU 'strongly condemns' US sanctions against five Europeans
-
Arsenal's Kepa Arrizabalaga eager for more League Cup heroics against Che;sea
-
Thailand-Cambodia border talks proceed after venue row
-
Kosovo, Serbia 'need to normalise' relations: Kosovo PM to AFP
-
Newcastle boss Howe takes no comfort from recent Man Utd record
-
Frank warns squad to be 'grown-up' as Spurs players get Christmas Day off
-
Rome pushes Meta to allow other AIs on WhatsApp
-
Black box recovered from Libyan general's crashed plane
-
Festive lights, security tight for Christmas in Damascus
-
Zelensky reveals US-Ukraine plan to end Russian war, key questions remain
-
El Salvador defends mega-prison key to Trump deportations
-
Stranger Things set for final bow: five things to know
-
Grief, trauma weigh on survivors of catastrophic Hong Kong fire
-
Asian markets mixed after US growth data fuels Wall St record
-
Stokes says England player welfare his main priority
-
Australia's Lyon determined to bounce back after surgery
-
Stokes says England players' welfare his main priority
-
North Korean POWs in Ukraine seeking 'new life' in South
-
Japanese golf star 'Jumbo' Ozaki dies aged 78
-
Johnson, Castle shine as Spurs rout Thunder
-
Thai border clashes hit tourism at Cambodia's Angkor temples
-
From predator to plate: Japan bear crisis sparks culinary craze
-
Asian markets mostly up after US growth fuels Wall St record
-
'Happy milestone': Pakistan's historic brewery cheers export licence
-
Chevron: the only foreign oil company left in Venezuela
-
US denies visas to EU ex-commissioner, four others over tech rules
-
Dynamite Blockchain Delivers Record Q3 2025
-
Cosmos Health Is Building a Platform, and Tariffs Are Accelerating the Strategy
-
SMX's Integrated Value Proposition: One System, Many Markets, Compounding Leverage
-
Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
-
Goldgroup Secures Ownership of the San Francisco Gold Mine Acquiring 100% of Molimentales del Noroeste, S.A. De C.V.
-
Alta Copper Announces Filing and Mailing of Meeting Materials for the Special Meeting of Shareholders and Optionholders to be Held on January 26, 2026
-
Pantheon Resources PLC Announces TR-1: Notification of Major Holdings
-
Bridgeline Expands Footprint with Closeout Retailer Choosing HawkSearch for Its On-Site Search Experience and Personalization
-
Koepka leaves LIV Golf: official
-
US slams China policies on chips but will delay tariffs to 2027
-
Arsenal reach League Cup semis with shoot-out win over Palace
-
Contenders Senegal, Nigeria start Cup of Nations campaigns with wins
-
Tunisia ease past Uganda to win Cup of Nations opener
-
S&P 500 surges to record after strong US economic report
-
UK police say no action against Bob Vylan duo over Israel army chant
-
Libya's top military chief killed in plane crash in Turkey
-
Venezuela passes law to jail backers of US oil blockade
-
French parliament passes emergency budget extension
Trump announces Pfizer deal he says will lower certain drug prices
The Trump administration on Tuesday announced a deal granting Pfizer a three-year reprieve on planned tariffs as the pharmaceutical giant vowed to voluntarily lower the prices of unspecified drugs for US purchase.
President Donald Trump, flanked by top health officials, was scant on details regarding what or how many drugs were included in the agreement, the announcement of which came as Washington faced a looming government shutdown.
Under the deal Pfizer is to charge "Most Favored Nation" pricing -- matching the lowest price offered in other wealthy nations -- to Medicaid, the US health insurance program for low-income Americans.
The White House also said it would unveil a website -- called TrumpRx -- that would allow consumers to directly purchase some medications from manufacturers at discounted rates.
Like Trump, Pfizer CEO Albert Bourla heralded the deal as a great achievement, although a statement from the company was equally vague on specifics.
The company did say a "large majority" of "primary care treatments and some select specialty brands" could be offered at savings from 50 percent to 85 percent.
"We now have the certainty and stability we need on two critical fronts, tariffs and pricing, that have suppressed the industry's valuations to historic lows," said Bourla.
Part of the deal included Pfizer agreeing to "invest $70 billion to reshore domestic manufacturing facilities" to the United States.
- Wider impact unclear -
Trump's initiative revives drug-pricing efforts from his first term. The president has taken steps since returning to the White House to pressure pharmaceutical companies into voluntarily lowering their prices.
In July the US leader sent letters to leading pharmaceutical companies demanding they lower drug prices.
Democrats have long indicated that they, too, would like to lower drug prices.
In a report released Monday, independent Senator Bernie Sanders said that Trump's efforts on the issue had "made headlines" but had done "little beyond that."
The member of the Senate's health committee said in his report that since Trump sent the letters over the summer, the prices of 87 drugs actually increased.
Drug costs for consumers in the United States can depend on several variables, notably insurance coverage.
Many people receive insurance through an employer, the health insurance market or government programs including Medicare, which is for seniors, and the safety net Medicaid.
It is not clear how Tuesday's deal will impact drug pricing in the commercial insurance market.
The announcement comes as drugmakers gird for a 100-percent tariff Trump said he would impose on branded pharmaceutical products entering the country from October 1 -- unless companies were building manufacturing plants in the United States.
But details surrounding the rollout remain unclear.
Since returning to the presidency in January, Trump has imposed sector-specific tariffs on imports like steel, aluminum and autos, while launching investigations into other areas like pharmaceuticals that could lead to new levies.
Asked Tuesday about the timeline for fresh tariffs, Commerce Secretary Howard Lutnick said the Trump administration plans to allow negotiations with companies to play out.
J.Williams--AMWN